Amphastar Pharmaceuticals, Inc. - 8-K Filing
Amphastar Pharmaceuticals reports Q3 2026 net revenues of $207.6 million and GAAP net income of $37.8 million. (Items: 2.02 Results of Operations and Financial Condition, 9.01 Financial Statements and Exhibits)
Tickers: $AMPH
Read the full article at SEC EDGAR
Part of the story DORCHESTER MINERALS, L.P. - 8-K Filing (3 articles)